AstraZeneca announces plans for a $1.5 billion manufacturing facility in Singapore for ADCs

AstraZeneca shared on LinkedIn:

“We are excited to announce our plans for a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs). ADCs are a class of drugs designed as a targeted therapy for treating cancer. .

This new facility will further enhance our world-class supply chain. The planned greenfield facility, supported by the Singapore Economic Development Board (EDB), will be designed to emit zero carbon from its first day of operations and will be the first end-to-end ADC production site in our global manufacturing and supply network.”

Source: AstraZeneca/LinkedIn